Urocit-K 540mg strength is approved for sale in Canada and is indicated for the treatment of calcium and uric acid kidney stones. Financial terms of the deal were not disclosed. In the US, Urocit-K is available in 540mg and 1080mg strengths.
Jonathan Goodman, president and CEO of Paladin, said: “We intend to launch Urocit-K 540mg and submit the 1,080mg formulation for approval in 2009. Urocit-K complements our broad urology franchise which includes Testim for the treatment of male hypogonadism and Trelstar for the treatment of prostate cancer. We expect Urocit-K to fulfill an unmet need for kidney stone patients in Canada.”